Sinusitis treatment drugs market valued at about USD 2.1 billion in 2019 and expected to reach about USD 2.9 billion by 2029 with an estimated CAGR of 3% during the forecast period of 2021 to 2029.
Immunization of livestock has been carried out worldwide for centuries and is also accepted as a cost effective measure of controlling infections. Until recently, vaccines were either live attenuated or inactivated organisms formulated with oil-based adjuvant; however these methods and formulations were not very effective.
The global point of purchase displays market expected to expand at a CAGR of 5.9% during the forecast period from 2018 to 2026. The projected growth will be majorly driven by the continual efforts taken by brand owners to aggressively promote and market their newly launched or seasonal products at retail outlets.
The global active pharmaceutical ingredient market is growing significantly, valuing at US$ 152.6 Bn in 2017 and expected to reach US$ 273.7 Bn by 2026. Worldwide growing chronic diseases along with rising incidences for respiratory, cardiovascular, and oncology drives the overall market growth during the forecast period. In addition, new technological progresses in biologics & other specialty drugs along with favorable public and private funding in the pharmaceutical sector across various developing countries will further assist in the API market growth.
Odor control systems market value expected to hit US$ 4,070.5 Mn by 2026, expanding with a CAGR of 3.6% during the forecast period from 2018 to 2026. Principally governed by Asia Pacific, odor control systems market majorly driven by rising regulations for environmental protection by several governing bodies.
Bio-based polyethylene terephthalate (PET) market projected to exhibit the CAGR of 20.8% during the forecast period from 2018 to 2026. Bio-based polyethylene terephthalate (PET) market is currently gaining traction owing to rising demand for eco-friendly sustainable solution from end-use industries coupled with growing public awareness and increasing customer interest in bio-based plastics.
The global pulmonary arterial hypertension (PAH) treatment market accounted for a value of US$ 10,174.9 Mn in 2021 and expected to attain US$ 19,093.2 Mn by 2033. Drivers accountable for the market growth are worldwide growing elderly population along with increasing prevalence of pulmonary arterial hypertension due to rising risk factors such as connective tissue disorders, human immunodeficiency virus (HIV) infection, chronic liver diseases, lung diseases, sedentary lifestyle, and other idiopathic conditions.
Human race is facing a monstrous issue of water scarcity and water treatment plant is one of the few ways out of this calamity humans have brought onto themselves. Setting up water treatment plants allow some amount of wastewater to be used again for essential and lifesaving application.
In the U.S. the prevalence of pressure ulcers in intensive care units ranges from 16.6% to 20.7%. It is also reported that annually US$ 11 billion is spent on the treatment of pressure ulcers, with US$ 500 to US$ 70,000 spent on a single wound. In spite of availability of better assessment tools, new CMS ruling eliminating hospital reimbursement when stage 3 or 4 pressure ulcer is hospital acquired and emergence of new technologies to reduce pressure ulcers, the condition remains a significant healthcare problem.
RFID tags market worldwide is set to register robust CAGR through the forecast period from 2025 to 2033, rising from US$ 5,955.8 Mn in 2020. RFID tags are electronic devices embedded with an antenna attached to the goods/animals/personnel to be tracked. The demand for RFID tags is primarily governed by the continually growing penetration of RFID tracking systems worldwide.
The drugs by therapeutic area include therapy for oncology, cardiovascular, central nervous system, infectious diseases, respiratory, and others. The therapeutic area represents the specific area of medicine where the drug is intended to be used, based on its mechanism of action and intended clinical use. One of the primary drivers of the drugs by therapeutic area market is the increasing prevalence of diseases worldwide. Chronic diseases such as cancer, cardiovascular diseases, and neurological disorders are a significant burden on healthcare systems globally. There is an urgent need for new and effective therapies to treat these diseases, which has led to the growth of the drugs in the therapeutic area market.
The revenues generated by the drugs in the therapeutic area market have been consistently high over the years. The global pharmaceutical market is expected to reach USD 1.5 trillion by 2023, with oncology being the leading therapeutic area. The increasing demand for new therapies, coupled with advancements in technology and an increasing focus on personalized medicine, is expected to drive the growth of the market in the coming years. One of the emerging trends in the drugs by therapeutic area market is the increasing use of precision medicine. Precision medicine involves tailoring medical treatments to individual patients based on their unique genetic and molecular profiles. The development of precision medicine requires the use of advanced diagnostic tools and drug discovery technologies, which have contributed to the growth of drugs in the therapeutic area market.
Another trend in the drugs by therapeutic area market is the increasing focus on biologics. Biologics are drugs that are produced from living cells and are used to treat a wide range of diseases, including cancer and autoimmune disorders. Biologics are more complex than traditional small-molecule drugs, and their development requires specialized manufacturing processes and clinical trial design. The increasing demand for biologics has contributed to the growth of the drugs by therapeutic area market. The increasing focus on rare diseases is also driving the growth of the drugs by therapeutic area market. Rare diseases are defined as diseases that affect fewer than 200,000 people in the United States. Although each rare disease affects a small number of people, there are over 7,000 rare diseases, which together affect millions of people worldwide. There is an urgent need for new therapies to treat rare diseases, which has led to the growth of drugs in the therapeutic area market.
The increasing use of combination therapies is driving the growth of the drugs by therapeutic area market. Combination therapies involve the use of two or more drugs to treat a disease. Combination therapies can improve patient outcomes by targeting multiple pathways involved in the disease process. The development of combination therapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the drugs by therapeutic area market. The increasing prevalence of diseases worldwide, advancements in technology, and the emerging trends in precision medicine, biologics, rare diseases, and combination therapies are expected to drive the growth of the drugs by therapeutic area market.
